T2 Biosystems announces plans to license technology to expand its leadership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
T2 Biosystems' Licensing Plans: T2 Biosystems is set to license its proprietary technology to enhance its position in the direct-from-whole-blood detection of sepsis-causing pathogens.
FDA-Cleared Products: The company's technology is integral to its FDA-cleared products, which are the first and only ones capable of detecting sepsis-causing pathogens directly from whole blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
